Prostate Cancer

Josep Maria Piulats Rodriguez, MD, discusses an analysis evaluating predictive biomarkers for treatment with talazoparib plus enzalutamide in mCRPC.

Phillip J. Koo, MD, discusses the utility of next-generation imaging in prostate cancer, highlighting the use of PSMA PET in this patient population.

Phillip J. Koo, MD, discusses the clinical use of PSMA PET imaging in patients with prostate cancer.

FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.

A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.

Ruben Olivares, MD, discusses the integration of focal therapy in the treatment of patients with intermediate prostate cancer.

Phillip J. Koo, MD, highlights future directions regarding PSMA PET imaging and key takeaways from a presentation he gave on the precision imaging tool.

Daniel Spratt, MD, discusses how evolving radiation therapy techniques in prostate cancer can reduce adverse effects and shorten treatment courses.

Phillip J. Koo, MD, discusses how PSMA PET will be used in clinical trials, the RADAR VI guidelines for using the precision imaging tool, and more.

Gautam Jha, MD, discusses collaborative efforts between community and academic oncologists to accrue patients to the ECLIPSE trial.

Emmanuel Antonarakis, MD, and Gautam Jha, MD, on collaboration efforts extending the reach of clinical trials beyond university hospitals.

Daniel Spratt, MD, discusses ongoing debate and uncertainties regarding the optimal use of treatment intensification in high-risk prostate cancer.

James Knight, MD, discusses a case study of a patient with brain-metastatic prostate adenocarcinoma.

Emmanuel Antonarakis, MD, discusses community enrollment in the ECLIPSE trial in prostate cancer.

Gautam Jha, MD, and Emmanuel Antonarakis, MD, on the advantages of collaborative efforts between community and academic oncologists.

Minesh Mehta, MD, discusses recent advancements in radiation oncology approaches for patients with prostate cancer.

Minesh Mehta, MD, discusses how MRI-guided adaptive radiation therapy systems may improve disease outcomes in cancer care.

Ruben Olivares, MD, discusses the evolving role for focal radiation therapy in the management of prostate cancer.

Neeraj Agarwal, MD, FASCO, discusses unmet needs across the prostate cancer spectrum and ongoing trials investigating agents in earlier settings.

Phillip J. Koo, MD, discusses the use of PSMA PET imaging in prostate cancer.

Daniel Spratt, MD, discusses the integration of metastasis-directed therapy and hypofractionation in prostate cancer.

Robert Dreicer, MD, discusses the complex landscape of prostate cancer treatment, highlighting key points from his presentation at the 2024 NY GU.

Mary-Ellen Taplin, MD, discusses ways to mitigate health care disparities in the treatment of patients with prostate cancer.

Daniel Spratt, MD, discusses the use of radiation therapy in low- and high-risk prostate cancer.

Philip J. Koo, MD, discusses the treatment of patients with prostate cancer throughout the different stages of their disease.